Questions About Cancer? 1-800-4-CANCER

Adult Hodgkin Lymphoma Treatment (PDQ®)

Health Professional Version
Last Modified: 02/28/2014

General Information About Adult Hodgkin Lymphoma

Incidence and Mortality
Prognosis and Survival Factors
Related Summaries



Incidence and Mortality

Estimated new cases and deaths from Hodgkin lymphoma in the United States in 2014:[1]

  • New cases: 9,190.
  • Deaths: 1,180.

More than 75% of all newly diagnosed patients with adult Hodgkin lymphoma (HL) can be cured with combination chemotherapy and/or radiation therapy.[2] National mortality has fallen more rapidly for adult HL than for any other malignancy over the last 5 decades.[2]

Prognosis and Survival Factors

Prognosis for a given patient depends on several factors. The most important factors are the presence or absence of systemic symptoms, the stage of disease, presence of large masses, and the quality and suitability of the treatment administered. Other important factors are age, sex, erythrocyte sedimentation rate, extent of abdominal involvement, hematocrit, and absolute number of nodal sites of involvement.[3-5]

HL is the main cause of death over the first 15 years after treatment. By 15 to 20 years after therapy, the cumulative mortality from a second malignancy will exceed the cumulative mortality from HL.[6-8]

Related Summaries

Other PDQ summaries containing information related to Hodgkin lymphoma include the following:

References
  1. American Cancer Society.: Cancer Facts and Figures 2014. Atlanta, Ga: American Cancer Society, 2014. Available online. Last accessed March 26, 2014. 

  2. Brenner H, Gondos A, Pulte D: Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111 (6): 2977-83, 2008.  [PUBMED Abstract]

  3. American Cancer Society.: Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007. Also available online. Last accessed October 7, 2013. 

  4. Cosset JM, Henry-Amar M, Meerwaldt JH, et al.: The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 28A (11): 1847-50, 1992.  [PUBMED Abstract]

  5. Evens AM, Helenowski I, Ramsdale E, et al.: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119 (3): 692-5, 2012.  [PUBMED Abstract]

  6. Mauch PM, Kalish LA, Marcus KC, et al.: Long-Term Survival in Hodgkin's Disease Cancer J Sci Am 1 (1): 33-42, 1995.  [PUBMED Abstract]

  7. Aisenberg AC: Problems in Hodgkin's disease management. Blood 93 (3): 761-79, 1999.  [PUBMED Abstract]

  8. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (18): 3431-9, 2003.  [PUBMED Abstract]